Literature DB >> 12210061

Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity.

Nadia Zaffaroni1, Chiara Della Porta, Raffaella Villa, Claudio Botti, Simonetta Buglioni, Marcella Mottolese, Maria Grazia Daidone.   

Abstract

Telomerase activity was determined in 15 breast cancers, 24 benign breast lesions, and 36 breast tissues adjacent to benign or malignant tumours. A positive TRAP (telomeric repeat amplification protocol) signal was detected in 67% of carcinomas and 29% of benign tumours. In five of ten cases, non-invaded breast tissues adjacent to telomerase-positive carcinomas also displayed telomerase activity. Conversely, in peritumoural specimens adjacent to benign lesions, telomerase activity was never detected. To investigate the regulatory mechanisms of telomerase activity in breast tissues, the expression of telomerase subunits was assessed, as well as the presence of alternatively spliced variants of human telomerase reverse transcriptase (hTERT). The presence of the hTERT full-length transcript appeared necessary for telomerase activity in breast carcinomas. Specifically, all telomerase-positive carcinomas expressed the hTERT full-length message, together with different combinations of alternatively spliced variants, whereas in telomerase-negative cancers, the hTERT full-length transcript was not detectable, or its abundance was markedly lower than that of alternatively spliced variants. Results obtained in benign tumours and normal tissues surrounding carcinomas instead showed that the presence of hTERT full-length transcript was not sufficient to determine telomerase activity. These findings suggest that in non-neoplastic tissues there are other mechanisms that suppress telomerase activity downstream from hTERT transcription and mRNA splicing and that such mechanisms have been lost during neoplastic transformation. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210061     DOI: 10.1002/path.1178

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  Colony forming unit endothelial cells do not exhibit telomerase alternative splicing variants and activity.

Authors:  Armin Attar; Mohsen Khosravi Maharlooi; Sara Khoshkhou; Ahmad Hosseini; Mansoureh Jaberipour; Arman Dehghan; Ahmad Monabati
Journal:  Iran Biomed J       Date:  2013

2.  Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Authors:  Hei Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Kyu Hyun Park; Tae Soo Kim; Jin Ju Kim; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

4.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Authors:  Yongchun Wang; Jeanne Kowalski; Hua-Ling Tsai; Radharani Marik; Nijaguna Prasad; Helina Somervell; Pang-Kuo Lo; Lauren E Sangenario; Lars Dyrskjot; Torben F Orntoft; William H Westra; Alan K Meeker; James R Eshleman; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

5.  Alternative splicing regulation of telomerase: a new paradigm?

Authors:  Mandy S Wong; Woodring E Wright; Jerry W Shay
Journal:  Trends Genet       Date:  2014-08-26       Impact factor: 11.639

6.  Canis familiaris telomerase reverse transcriptase undergoes alternative splicing.

Authors:  Katerina Angelopoulou; Michael Zavlaris; Nikolaos Papaioannou; Ioannis Vlemmas
Journal:  Mamm Genome       Date:  2008-10-04       Impact factor: 2.957

7.  Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues.

Authors:  Stein Saebøe-Larssen; Ellen Fossberg; Gustav Gaudernack
Journal:  BMC Mol Biol       Date:  2006-08-29       Impact factor: 2.946

8.  Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells.

Authors:  J H Ohyashiki; H Hisatomi; K Nagao; S Honda; T Takaku; Y Zhang; G Sashida; K Ohyashiki
Journal:  Br J Cancer       Date:  2005-05-23       Impact factor: 7.640

Review 9.  Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.

Authors:  Yoshiko Maida; Kenkichi Masutomi
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

Review 10.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.